Research programme: peptide therapeutics - Pacgen
Alternative Names: PAC 525; PAC 745; PAC G31PLatest Information Update: 16 Jul 2016
At a glance
- Originator Pacgen Biopharmaceuticals
- Developer Pacgen Life Science Corporation
- Class Peptides
- Mechanism of Action Cytokine receptor antagonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections; Inflammation; Viral hepatitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in Canada
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Canada
- 16 Jul 2016 No recent reports of development identified for preclinical development in Viral-hepatitis in Canada